Dr. Reddy's Launches Novel Molecule 'Tegoprazan' in India for Acid-related Gastrointestinal Diseases
Dr. Reddy's Laboratories Ltd. has announced the launch of the novel molecule ‘Tegoprazan’ in India for the treatment of acid peptic diseases (APD) such as Erosive Gastroesophageal Reflux Disease (GERD), Non-Erosive Gastroesophageal Reflux Disease (NERD) and Gastric Ulcer. The launch follows Dr. Reddy’s exclusive partnership in 2022 with South Korea-based HK inno.N Corporation to commercialize Tegoprazan in India & select Emerging Markets. In a multinational clinical trial, 99% of GERD patients in the Tegoprazan treatment arm achieved endoscopic healing by Week 8. Tegoprazan is already approved in 21 countries, including South Korea and China, and is currently under registration in several countries. It has successfully completed Phase-lll trial in the United States.
Key Highlights
- Dr. Reddy's launches novel molecule ‘Tegoprazan’ in India for acid-related gastrointestinal diseases.
- Tegoprazan is a next-generation potassium-competitive acid blocker indicated for the treatment of APD such as GERD, NERD and Gastric Ulcer.
- In a multinational clinical trial, 99% of GERD patients in the Tegoprazan treatment arm achieved endoscopic healing by Week 8.
- Tegoprazan is already approved in 21 countries, including South Korea and China, and is currently under registration in several countries.
- Tegoprazan has successfully completed Phase-lll trial in the United States.